• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright reiterated coverage on BioNTech with a new price target

    6/5/25 11:30:01 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BNTX alert in real time by email
    H.C. Wainwright reiterated coverage of BioNTech with a rating of Buy and set a new price target of $145.00 from $134.00 previously
    Get the next $BNTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BNTX

    DatePrice TargetRatingAnalyst
    6/5/2025$134.00 → $145.00Buy
    H.C. Wainwright
    5/29/2025$110.00Neutral
    Goldman
    3/13/2025$145.00Buy
    Citigroup
    1/10/2025$172.00Buy
    Truist
    12/11/2024$170.00Overweight
    Wells Fargo
    12/2/2024Outperform
    BMO Capital Markets
    11/19/2024$130.00Buy
    Berenberg
    11/19/2024$110.00 → $125.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $BNTX
    SEC Filings

    See more
    • SEC Form 6-K filed by BioNTech SE

      6-K - BioNTech SE (0001776985) (Filer)

      7/25/25 8:53:17 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by BioNTech SE

      6-K - BioNTech SE (0001776985) (Filer)

      7/17/25 8:32:53 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by BioNTech SE

      6-K - BioNTech SE (0001776985) (Filer)

      6/17/25 4:40:42 PM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BNTX
    Financials

    Live finance-specific insights

    See more
    • BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025

      MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via

      7/21/25 6:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

      Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech's combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates ("ADCs") Development and commercial preparation for a 2025/2026 season variant-adapted COVID-19 vaccine First quarter 2025 revenues of €0.2 billion2, net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823) Maintained strong financial positio

      5/5/25 6:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

      MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via thi

      4/22/25 6:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BNTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioNTech SE

      SC 13G/A - BioNTech SE (0001776985) (Subject)

      11/13/24 5:00:57 PM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by BioNTech SE

      SC 13D - BioNTech SE (0001776985) (Filed by)

      2/21/24 5:01:33 PM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BioNTech SE (Amendment)

      SC 13G/A - BioNTech SE (0001776985) (Subject)

      2/14/24 7:26:25 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on BioNTech with a new price target

      H.C. Wainwright reiterated coverage of BioNTech with a rating of Buy and set a new price target of $145.00 from $134.00 previously

      6/5/25 11:30:01 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on BioNTech with a new price target

      Goldman initiated coverage of BioNTech with a rating of Neutral and set a new price target of $110.00

      5/29/25 8:17:23 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Citigroup initiated coverage on BioNTech with a new price target

      Citigroup initiated coverage of BioNTech with a rating of Buy and set a new price target of $145.00

      3/13/25 7:26:20 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BNTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

      Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulationsUpon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and olderTo date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance and manufacturing dataDoses will be ready to sh

      7/25/25 2:30:00 AM ET
      $BNTX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

      Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulations Upon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and older To date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance and manufacturing data Doses will

      7/25/25 2:30:00 AM ET
      $BNTX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025

      MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via

      7/21/25 6:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BNTX
    Leadership Updates

    Live Leadership Updates

    See more
    • BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

      Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer ("CFO") effective July 1, 2025. He will join BioNTech from Novartis AG's global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June 30, 2025. In his new role as CFO at BioNTech, Ramón Zapata will ensure the Company's financial direction continues to align with BioNTech's strategy to become a multi-product company i

      5/5/25 6:30:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioNTech to Acquire Biotheus to Boost Oncology Strategy

      Acquisition to support the global execution of BioNTech's oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumorsWith the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinationsBioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 202

      11/13/24 6:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioNTech to Host Innovation Series R&D Day on November 14, 2024

      MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S. On the day, BioNTech's leadership team will provide an overview of the Company's corporate strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this link. A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company's website for one yea

      10/31/24 7:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care